TG Therapeutics Inc (NASDAQ: TGTX) is -0.80% lower on its value in year-to-date trading and has touched a low of $12.84 and a high of $36.84 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TGTX stock was last observed hovering at around $29.55 in the last trading session, with the day’s gains setting it 0.31%.
Currently trading at $29.86, the stock is -1.46% and -5.15% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.1 million and changing 1.05% at the moment leaves the stock 31.34% off its SMA200. TGTX registered 97.23% gain for a year compared to 6-month gain of 42.19%. The firm has a 50-day simple moving average (SMA 50) of $31.4015 and a 200-day simple moving average (SMA200) of $22.657825.
The stock witnessed a -11.05% loss in the last 1 month and extending the period to 3 months gives it a 24.73%, and is 7.91% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.94% over the week and 5.33% over the month.
TG Therapeutics Inc (TGTX) has around 264 employees, a market worth around $4.65B and $264.79M in sales. Fwd P/E is 29.42. Profit margin for the company is -5.42%. Distance from 52-week low is 132.55% and -18.95% from its 52-week high. The company has generated returns on investments over the last 12 months (-3.23%).
with sales reaching $99.36M over the same period.The EPS is expected to grow by 22.22% this year, but quarterly earnings will post 37.05% year-over-year. Quarterly sales are estimated to grow 125.97% in year-over-year returns.
TG Therapeutics Inc (TGTX) Top Institutional Holders
389.0 institutions hold shares in TG Therapeutics Inc (TGTX), with institutional investors hold 73.17% of the company’s shares. The shares outstanding are 155.78M, and float is at 140.52M with Short Float at 18.50%. Institutions hold 66.22% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 13.69 million shares valued at $243.58 million. The investor’s holdings represent 9.3645% of the TGTX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 11.39 million shares valued at $202.6 million to account for 7.7891 of the shares outstanding. The other top investors are STATE STREET CORP which holds 6.7 million shares representing 4.5798% and valued at over $119.12 million, while SOLEUS CAPITAL MANAGEMENT, L.P. holds 2.4934 of the shares totaling 3.65 million with a market value of $64.85 million.
TG Therapeutics Inc (TGTX) Insider Activity
The most recent transaction is an insider sale by Power Sean A, the company’s CFO. SEC filings show that Power Sean A sold 11,337 shares of the company’s common stock on Jan 03 ’25 at a price of $30.29 per share for a total of $0.34 million. Following the sale, the insider now owns 0.67 million shares.
TG Therapeutics Inc disclosed in a document filed with the SEC on Jan 06 ’25 that Power Sean A (CFO) sold a total of 10,021 shares of the company’s common stock. The trade occurred on Jan 06 ’25 and was made at $28.53 per share for $0.29 million. Following the transaction, the insider now directly holds 0.66 million shares of the TGTX stock.
Still, SEC filings show that on Jan 06 ’25, Power Sean A (Officer) Proposed Sale 10,021 shares at an average price of $28.53 for $0.29 million. The insider now directly holds shares of TG Therapeutics Inc (TGTX).
